Zai Lab (ZLAB) Stock News, May-Aug 2025

Zai Lab (NASDAQ: ZLAB) reported Q2 2025 financial results with total revenues growing 9% year-over-year to $110.0 million. The company reaffirmed its full-year 2025 revenue guidance of $560-590 million. Operating loss improved by 28% year-over-year to $54.9 million, with the company on track to achieve profitability in Q4 2025.

Key highlights include VYVGART's record patient utilization and ZL-1310's promising clinical data showing 67% overall response rate in second-line SCLC. The successful Phase 3 FORTITUDE-101 study of bemarituzumab in gastric cancer met its primary endpoint, with China regulatory submission expected in H2 2025.

The company maintains a strong financial position with $832.3 million in cash and equivalents as of June 30, 2025, supporting its commercial expansion and pipeline development.

Zai Lab (NASDAQ: ZLAB; HKEX: 9688) has scheduled its second quarter 2025 financial results announcement and corporate updates for August 7, 2025, before U.S. markets open. The company will host a conference call and webcast at 8:00 a.m. ET (8:00 p.m. HKT) on the same day.

Interested participants must register in advance through the provided links to access either the webcast or dial-in options. A replay of the event will be available on the company's website after the call.

Zai Lab (NASDAQ: ZLAB) announced positive Phase 3 results for bemarituzumab in treating FGFR2b-positive first-line gastric cancer. The FORTITUDE-101 clinical trial demonstrated that bemarituzumab plus chemotherapy achieved a statistically significant and clinically meaningful improvement in overall survival compared to placebo plus chemotherapy in patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction cancer.

The study focused on patients with FGFR2b overexpression (defined as 2+/3+ staining in ≥10% of tumor cells) who are non-HER2 positive. Bemarituzumab is the first FGFR2b inhibitor to show significant overall survival benefit in a Phase 3 trial for first-line treatment of FGFR2b-positive gastric cancer.

The most common adverse events included reduced visual acuity, punctate keratitis, anemia, neutropenia, nausea, corneal epithelium defect, and dry eye. Ocular events occurred with greater frequency and severity in the bemarituzumab arm. The company plans to pursue regulatory submission in China, where the drug has already received Breakthrough Therapy designation.

Zai Lab (NASDAQ: ZLAB) presented promising preclinical data for ZL-1503, their IL-13/IL-31R bispecific antibody for treating moderate-to-severe atopic dermatitis, at EAACI Congress 2025. The study demonstrated ZL-1503's ability to simultaneously suppress both inflammatory and itch-causing pathways. Key findings showed that a single 10 mg/kg dose completely inhibited target pathways for at least 76 days, with some subjects showing effects beyond 118 days. The drug exhibited slow clearance, strong pharmacokinetic/pharmacodynamic relationships, and was well-tolerated at doses up to 150 mg/kg. Zai Lab plans to file an IND by the end of 2025, positioning ZL-1503 as a potential advancement over current treatments that only partially alleviate symptoms through IL-4/IL-13 inhibition alone.

Zai Lab (ZLAB) presented promising Phase 1 data for ZL-1310, a DLL3-targeted ADC, in treating extensive-stage small cell lung cancer (ES-SCLC) at ASCO 2025. The drug showed remarkable efficacy with a 67% objective response rate in second-line treatment across all doses, and 79% at the optimal 1.6 mg/kg dose. Among 89 patients studied, ZL-1310 demonstrated strong safety at doses below 2.0 mg/kg, with only 6% Grade ≥3 treatment-related adverse events and no discontinuations. Notably, 68% of patients with brain metastases responded to treatment. The drug maintained efficacy in heavily pretreated patients, with 89% experiencing tumor reduction. Based on these positive results, Zai Lab plans to initiate a pivotal trial in second-line ES-SCLC later this year, with potential regulatory submission by 2026.

Zai Lab and Novocure announced positive Phase 3 PANOVA-3 trial results for Tumor Treating Fields (TTFields) therapy in pancreatic cancer treatment. The trial, combining TTFields with gemcitabine and nab-paclitaxel, demonstrated significant improvement in overall survival for patients with unresectable, locally advanced pancreatic adenocarcinoma. The study showed median overall survival of 16.2 months versus 14.2 months in the control group (HR 0.82; p=0.039). Notable improvements included one-year survival rate (68.1% vs 60.2%) and pain-free survival (15.2 vs 9.1 months). The therapy was well-tolerated with only mild to moderate skin adverse events. Novocure plans to submit data to FDA in second half of 2025 for premarket approval. The results will be presented at the 2025 ASCO Annual Meeting and published in the Journal of Clinical Oncology.

Zai Lab (NASDAQ: ZLAB; HKEX: 9688) has announced its participation in three major healthcare investor conferences in June 2025. The company's senior management will attend the Jefferies Global Healthcare Conference in New York on June 4, featuring a fireside chat at 10:30 a.m. EST with a live webcast available. They will also participate in the Goldman Sachs 46th Annual Healthcare Conference in Miami on June 9, and the Scotiabank Third Annual Healthcare Canadian Investor Day in Toronto on June 17. Investors can access the fireside chat webcast on Zai Lab's Investor Relations website, with replays available for 90 days post-event.

Zai Lab (NASDAQ: ZLAB) has received Fast Track designation from the FDA for ZL-1310, its DLL3-targeted antibody-drug conjugate (ADC) for treating extensive-stage small cell lung cancer (ES-SCLC). The drug previously received Orphan Drug designation for SCLC. The company plans to initiate a pivotal study in 2025, aiming for potential accelerated approval by 2027.

The Fast Track status enables more frequent FDA interactions and eligibility for Accelerated Approval and Priority Review. Zai Lab will present updated data at the 2025 ASCO Annual Meeting and host an investor conference call on June 2, 2025, to discuss clinical development plans.

Zai Lab reported strong Q1 2025 financial results with total revenues growing 22% year-over-year to $106.5 million. The company reaffirmed its full-year 2025 revenue guidance of $560-590 million. Operating loss improved significantly, declining 20% to $56.3 million. The company maintains a strong cash position of $857.3 million. Key product performances include VYVGART at $18.1 million (up from $13.2M), ZEJULA at $49.5 million (up from $45.5M), and NUZYRA at $15.1 million (up from $9.9M). The company's pipeline is advancing with promising developments in oncology therapies, including ZL-1310 (DLL3 ADC) with upcoming ASCO 2025 data presentation. Zai Lab expects to achieve profitability in Q4 2025 and is progressing toward becoming a leading global biopharmaceutical company with multiple upcoming catalysts and pipeline developments.